AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15122604 — intervention group
Group type: COMPARATOR
Intervention: Open fundoplication
Number of subjects: 60
Study 11934652 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE; 0.625 mg)
Number of subjects: 38
Study 11934652 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 38
Study 11934652 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 150 mg
Number of subjects: 38
Study 11934652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 9832936 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg caffeine
Number of subjects: 21
Study 9832936 — intervention group
Group type: COMPARATOR
Intervention: 0 mg nicotine
Number of subjects: 21
Study 9832936 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg nicotine
Number of subjects: 21
Study 9832936 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg nicotine
Number of subjects: 21
Study 9832936 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg nicotine
Number of subjects: 21
Study 9832936 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg nicotine
Number of subjects: 21
Study 7852227 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiopathic epilepsy patients on day 1 and day 4 of seizures
Number of subjects: 50
Study 7852227 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiopathic epilepsy patients on day 7 of seizures
Number of subjects: 50
Study 7852227 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe epilepsy and status epilepticus
Number of subjects: 50
Study 7852227 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild and moderate epilepsy
Number of subjects: 50
Study 7852227 — intervention group
Group type: COMPARATOR
Intervention: Normal healthy controls
Number of subjects: 50
Study 2838426 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iodized oil (2 ml)
Number of subjects: 5999
Study 2838426 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular iodized oil (2 ml)
Number of subjects: 5999
Study 2838426 — intervention group
Group type: COMPARATOR
Intervention: Potassium iodide (0.5 g, 1.0 g, and 2.0 g)
Number of subjects: 5999
Study 2838426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5999
Study 31055677 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual attention training (twice a week for 45 min sessions over 3 weeks)
Number of subjects: 30
Study 31055677 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 30
Study 28954842 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-Grain Wheat (WGW)
Number of subjects: 70
Study 28954842 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-Grain Rye (WGR)
Number of subjects: 70
Study 28954842 — intervention group
Group type: COMPARATOR
Intervention: Refined Wheat (RW)
Number of subjects: 70
Study 26493038 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐monthly fixed dosing of Ozurdex
Number of subjects: 100
Study 26493038 — intervention group
Group type: COMPARATOR
Intervention: OCT‐guided PRN regimen of Ozurdex
Number of subjects: 100
Study 21691780 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed reduction
Number of subjects: 40
Study 21691780 — intervention group
Group type: COMPARATOR
Intervention: Open reduction
Number of subjects: 40
Study 21577082 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual training group
Number of subjects: 20
Study 21577082 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 19566689 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice simulation experience
Number of subjects: 28
Study 16491463 — intervention group
Group type: EXPERIMENTAL
Intervention: Single phosphate enema
Number of subjects: 294
Study 16491463 — intervention group
Group type: COMPARATOR
Intervention: Oral polyethylene glycol (PEG) solution (3 litres)
Number of subjects: 294
Study 15243275 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (n = 87)
Number of subjects: 173
Study 15243275 — intervention group
Group type: COMPARATOR
Intervention: Stretching control group (n = 86)
Number of subjects: 173
Study 11395986 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly iron supplementation (FeSO4) for 18 weeks
Number of subjects: 73
Study 11395986 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 18 weeks
Number of subjects: 73
Study 9257425 — intervention group
Group type: EXPERIMENTAL
Intervention: Sargramostim (300 micrograms; 193 mg/m2)
Number of subjects: 137
Study 9257425 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim (481 mg; 7 mg/kg)
Number of subjects: 137
Study 9257425 — intervention group
Group type: EXPERIMENTAL
Intervention: Sargramostim and Filgrastim
Number of subjects: 137
Study 8400081 — intervention group
Group type: EXPERIMENTAL
Intervention: Complement-activating membrane
Number of subjects: 0
Study 8400081 — intervention group
Group type: COMPARATOR
Intervention: Noncomplement-activating membrane
Number of subjects: 0
Study 3037835 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ketoconazole (400 mg every 8 h)
Number of subjects: 7
Study 3037835 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ketoconazole (400 mg every 8 h) + Dexamethasone (0.5 mg twice daily)
Number of subjects: 7
Study 30791879 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based educational tool providing information on non-specific chronic low back pain
Number of subjects: 0
Study 30791879 — intervention group
Group type: COMPARATOR
Intervention: Video explaining clinical practice guidelines on low back pain
Number of subjects: 0
Study 27975209 — intervention group
Group type: EXPERIMENTAL
Intervention: Exendin (9-39) (Ex-9)
Number of subjects: 8
Study 27975209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 24435222 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing prosthesis
Number of subjects: 94
Study 24435222 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing prosthesis
Number of subjects: 94
Study 22986111 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 50
Study 22986111 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with adjunctive mitomycin C
Number of subjects: 50
Study 21432224 — intervention group
Group type: EXPERIMENTAL
Intervention: On-the-job training (OJT) with guidance by an orthopedist and an exercise instructor, and stretching exercises for 6 min every day.
Number of subjects: 88
Study 21432224 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 88
Study 19025306 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (SOM, 250 mg)
Number of subjects: 45
Study 19025306 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (OCT, 50 mg)
Number of subjects: 45
Study 19025306 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 45
Study 20087643 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 246
Study 20087643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 20087643 — intervention group
Group type: COMPARATOR
Intervention: Transdermal nicotine and behavioral counseling
Number of subjects: 246
Study 16366759 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 0
Study 16366759 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 0
Study 16366759 — intervention group
Group type: EXPERIMENTAL
Intervention: LAAM
Number of subjects: 0
Study 16366759 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 12091996 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim treatment
Number of subjects: 0
Study 12091996 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 12091996 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular treatment (without filgrastim)
Number of subjects: 0
Study 9494305 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextropropoxyphene (DPP) 120 mg to 240 mg daily
Number of subjects: 32
Study 9494305 — intervention group
Group type: COMPARATOR
Intervention: Controlled-release morphine 20 mg daily
Number of subjects: 32
Study 9494305 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextropropoxyphene (DPP)
Number of subjects: 32
Study 9494305 — intervention group
Group type: COMPARATOR
Intervention: Controlled-release morphine
Number of subjects: 32
Study 8036118 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral stimulus
Number of subjects: 0
Study 8036118 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsilateral stimulus
Number of subjects: 0
Study 8036118 — intervention group
Group type: EXPERIMENTAL
Intervention: Two stimuli with different intensities on the same tongue side
Number of subjects: 0
Study 8036118 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprathreshold stimuli
Number of subjects: 0
Study 3141290 — intervention group
Group type: EXPERIMENTAL
Intervention: bacampillin 800 mg b.i.d. for ten days
Number of subjects: 301
Study 3141290 — intervention group
Group type: COMPARATOR
Intervention: amoxicillin 500 mg t.i.d. for ten days
Number of subjects: 301
Study 3141290 — intervention group
Group type: COMPARATOR
Intervention: amoxicillin 500 mg t.i.d.
Number of subjects: 301
Study 3141290 — intervention group
Group type: EXPERIMENTAL
Intervention: bacampillin 800 mg b.i.d.
Number of subjects: 301
Study 30106834 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytology
Number of subjects: 101
Study 30106834 — intervention group
Group type: EXPERIMENTAL
Intervention: FISH
Number of subjects: 101
Study 30106834 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular Profiling (MP)
Number of subjects: 101
Study 30106834 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Cytology, FISH, and MP
Number of subjects: 101
Study 30106834 — intervention group
Group type: EXPERIMENTAL
Intervention: MP
Number of subjects: 101
Study 30106834 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of FISH and MP
Number of subjects: 101
Study 30128092 — intervention group
Group type: EXPERIMENTAL
Intervention: Persian Medicine Protocol (intranasal lavender oil, Liquorice Marjoram Tea)
Number of subjects: 42
Study 30128092 — intervention group
Group type: COMPARATOR
Intervention: Classical treatment (systemic and intranasal cortisone)
Number of subjects: 42
Study 30128092 — intervention group
Group type: EXPERIMENTAL
Intervention: Persian Medicine Protocol
Number of subjects: 42
Study 27769828 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic vapour product (EVP; 2.0% nicotine)
Number of subjects: 0
Study 24268300 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Education (IE)
Number of subjects: 134
Study 24268300 — intervention group
Group type: COMPARATOR
Intervention: Delayed Education (DE)
Number of subjects: 134
Study 22006207 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation (Swisse Women's 50+ Ultivite ®)
Number of subjects: 56
Study 19766948 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy (MST)
Number of subjects: 48
Study 19766948 — intervention group
Group type: COMPARATOR
Intervention: Group weight‐loss intervention (Control)
Number of subjects: 48
Study 17261560 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom fit semirigid insoles
Number of subjects: 31
Study 17261560 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy (10 treatments: deep‐friction, pulsed ultrasound, ice, sensory motor training)
Number of subjects: 31
Study 17261560 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 31
Study 15536619 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 1190
Study 15536619 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent smokers
Number of subjects: 1190
Study 15536619 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 1190
Study 15536619 — intervention group
Group type: EXPERIMENTAL
Intervention: Never-smokers
Number of subjects: 1190
Study 15536619 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who quit smoking within 12 months before randomization
Number of subjects: 1190
Study 15536619 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who were current smokers at randomization
Number of subjects: 1190
Study 15536619 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smokers and recent quitters who continued to abstain from smoking during follow-up
Number of subjects: 1190
Study 11260582 — intervention group
Group type: EXPERIMENTAL
Intervention: Child behavior informational intervention for mothers
Number of subjects: 49
Study 9543905 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education intervention (one-on-one education session by a nephrology nurse using a teaching booklet, Osteodystrophy Tool, and medication diary)
Number of subjects: 29
Study 9543905 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education intervention
Number of subjects: 29
Study 7509380 — intervention group
Group type: COMPARATOR
Intervention: Taxol (paclitaxel) 250 mg/m2 without G-CSF
Number of subjects: 35
Study 7509380 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxol (paclitaxel) 300 mg/m2 with G-CSF
Number of subjects: 35
Study 7509380 — intervention group
Group type: COMPARATOR
Intervention: Taxol (paclitaxel) 250 mg/m2
Number of subjects: 35
Study 7509380 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxol (paclitaxel)
Number of subjects: 35
Study 3132962 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic treatment with intracoronary streptokinase
Number of subjects: 533
Study 30012789 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 34
Study 30012789 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 34
Study 26832888 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone and Vitamin D
Number of subjects: 64
Study 26832888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 24684254 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic/endoscopic thyroidectomy (GUAB/GUA approaches)
Number of subjects: 147
Study 24684254 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic/endoscopic thyroidectomy (GUA approach)
Number of subjects: 147
Study 24684254 — intervention group
Group type: COMPARATOR
Intervention: Conventional open thyroidectomy
Number of subjects: 147
Study 23517257 — intervention group
Group type: COMPARATOR
Intervention: SCUBE‐1 levels at 2 hours (Group IV)
Number of subjects: 36
Study 23517257 — intervention group
Group type: COMPARATOR
Intervention: Total oxidative status (TOS) at 30 minutes and 2 hours
Number of subjects: 36
Study 23517257 — intervention group
Group type: COMPARATOR
Intervention: Oxidative stress index (OSI) at 30 minutes and 2 hours
Number of subjects: 36
Study 23517257 — intervention group
Group type: COMPARATOR
Intervention: SCUBE‐1 levels at 6 hours (Group VI)
Number of subjects: 36
Study 23517257 — intervention group
Group type: COMPARATOR
Intervention: MDA, TAS, TOS, and OSI levels
Number of subjects: 36
Study 20595563 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive knee instruments
Number of subjects: 134
Study 20595563 — intervention group
Group type: COMPARATOR
Intervention: Standard approach
Number of subjects: 134
Study 18450124 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 2000 microg nebulized budesonide
Number of subjects: 40
Study 18450124 — intervention group
Group type: COMPARATOR
Intervention: Repeated doses of 4 x 500 microg nebulized budesonide
Number of subjects: 40
Study 17162433 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard heparin
Number of subjects: 33
Study 17162433 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 33
Study 17162433 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anticoagulant)
Number of subjects: 33
Study 12225269 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0
Study 12225269 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolysed milk formulas
Number of subjects: 0
Study 12225269 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined dietary manipulation plus airborne allergen avoidance
Number of subjects: 0
Study 12225269 — intervention group
Group type: COMPARATOR
Intervention: Exclusive breastfeeding for three months
Number of subjects: 0
Study 12225269 — intervention group
Group type: COMPARATOR
Intervention: High intake of omega-3 fatty acids (regular fish consumption)
Number of subjects: 0
Study 10426453 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m2 plus doxorubicin 50 mg/m2
Number of subjects: 0
Study 10426453 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 60 mg/m2 plus doxorubicin 60 mg/m2
Number of subjects: 0
Study 10426453 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus doxorubicin
Number of subjects: 0
Study 10426453 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin plus cyclophosphamide
Number of subjects: 0
Study 8848891 — intervention group
Group type: EXPERIMENTAL
Intervention: mivacurium (150 and 70 micrograms kg‐1)
Number of subjects: 45
Study 8848891 — intervention group
Group type: EXPERIMENTAL
Intervention: mivacurium preceded by atracurium (350 and 75 micrograms kg‐1)
Number of subjects: 45
Study 8848891 — intervention group
Group type: EXPERIMENTAL
Intervention: mivacurium preceded by vecuronium (70 and 15 micrograms kg‐1)
Number of subjects: 45
Study 8848891 — intervention group
Group type: EXPERIMENTAL
Intervention: mivacurium (final dose 70 micrograms kg‐1)
Number of subjects: 45
Study 2194509 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% carbohydrate diet
Number of subjects: 11
Study 2194509 — intervention group
Group type: COMPARATOR
Intervention: 40% carbohydrate diet
Number of subjects: 11
Study 354329 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine enanthate (high doses, 10-20 times higher than normal)
Number of subjects: 12
Study 354329 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine enanthate (high doses)
Number of subjects: 12
Study 28636188 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 143
Study 28636188 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued on pressure lowering medication)
Number of subjects: 143
Study 27236073 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful acceptance induction
Number of subjects: 79
Study 27236073 — intervention group
Group type: COMPARATOR
Intervention: Thought wandering induction
Number of subjects: 79
Study 24357798 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-factor model including any two of the four intermediate-risk factors (tumour size ≥3 cm, DSI of the outer third of the cervix, LVSI, and adenocarcinoma or adenosquamous carcinoma histology)
Number of subjects: 2158
Study 24357798 — intervention group
Group type: EXPERIMENTAL
Intervention: Development group
Number of subjects: 2158
Study 24357798 — intervention group
Group type: COMPARATOR
Intervention: Validation group
Number of subjects: 2158
Study 24357798 — intervention group
Group type: EXPERIMENTAL
Intervention: Four factors (histology, tumour size, DSI, LVSI)
Number of subjects: 2158
Study 22101760 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (4 or 8 mg/kg intravenous infusions every 4 weeks for a total of 6 doses)
Number of subjects: 4
Study 22101760 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 4
Study 20637042 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter with a proposed date
Number of subjects: 3245
Study 20637042 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone call
Number of subjects: 3245
Study 20637042 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter without a proposed date
Number of subjects: 3245
Study 18676327 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiation
Number of subjects: 0
Study 18676327 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiation with gemcitabine
Number of subjects: 0
Study 18676327 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 16650792 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial Mediterranean fever (FMF) patients
Number of subjects: 98
Study 16650792 — intervention group
Group type: EXPERIMENTAL
Intervention: Behçet's disease (BD) patients
Number of subjects: 98
Study 16650792 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 98
Study 12786629 — intervention group
Group type: EXPERIMENTAL
Intervention: Repifermin 1 microg/kg
Number of subjects: 88
Study 12786629 — intervention group
Group type: EXPERIMENTAL
Intervention: Repifermin 5 microg/kg
Number of subjects: 88
Study 12786629 — intervention group
Group type: EXPERIMENTAL
Intervention: Repifermin 10 microg/kg
Number of subjects: 88
Study 12786629 — intervention group
Group type: EXPERIMENTAL
Intervention: Repifermin 25 microg/kg
Number of subjects: 88
Study 12786629 — intervention group
Group type: EXPERIMENTAL
Intervention: Repifermin 50 microg/kg
Number of subjects: 88
Study 12786629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 10999807 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine supplementation during pregnancy and postpartum (150 microg)
Number of subjects: 66
Study 10999807 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine supplementation during pregnancy only (150 microg)
Number of subjects: 66
Study 10999807 — intervention group
Group type: COMPARATOR
Intervention: No iodine supplementation
Number of subjects: 66
Study 9547125 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary packages of care for spouses of older people with psychiatric illness
Number of subjects: 0
Study 9547125 — intervention group
Group type: COMPARATOR
Intervention: No extra help (Control)
Number of subjects: 0
Study 8345382 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant administration by pump
Number of subjects: 22
Study 8345382 — intervention group
Group type: COMPARATOR
Intervention: Surfactant administration by hand-dosing method
Number of subjects: 22
Study 3088085 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education to improve asthma management at home
Number of subjects: 310
Study 3088085 — intervention group
Group type: COMPARATOR
Intervention: Control group (no health education)
Number of subjects: 310
Study 30509204 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Emergency Department Intervention (GEDI) model
Number of subjects: 44983